Dr Ashvind Prabahran

Learn more about Monash Health’s Haematology team.

Dr Ashvind Prabahran

Ashvind Prabahran is a Haematologist and BMT Physician with a special interest in myeloid disorders, bone marrow failure syndromes and allogeneic stem cell transplant. After completing clinical and laboratory training in Haematology, he was awarded the Maddie Riewoldt’s Vision/Victorian Cancer Agency Travelling Fellowship. Through this fellowship he completed a PhD through the ACRF laboratory at the Royal Melbourne Hospital and National Heart Lung and Blood Institute at the NIH in the United States. As part of this PhD he has published articles in the area of engraftment syndromes following allogeneic stem cell transplant and immune mediated bone marrow failure.

Top 5 publications

Prabahran A, Wu Z, Gao S, Morgan H, Holzwart N, Ludford-Menting M, Rawicki M, Klass, J, Koo R, Wilson C, Blombery P, Tan CW, Indukuri S, Chee L, Ritchie D, Young NS, Feng X, Koldej R. T cell and monocyte activation in concert with hematopoietic stem cell interactions shapes the post-allogeneic transplant immune landscape in poor graft function. Frontiers in Immunology. Jan 2026

Prabahran AA, Wu l, Lee Manley A, Wu Z, Gao S, Mizumaki H, Baena V, Syed Z, Combs C, Chen J, Feng X, Young N

Mature Megakaryocytes Acquire Immune Characteristics in a Mouse Model of Aplastic Anemia. Blood Advances 2025 Mar; Online ahead of print. DOI: 10.1182/bloodadvances.2024015621

Prabahran A, Durrani J, Coelho-Da Silva J, Shalhoub R, Lotter J, Rios O, Ritchie DS, Wu C, Patel B, Young N, Groarke EM.  Safety and efficacy of immunosuppressive therapy for elderly patients with severe aplastic anaemia. British Journal of Haematology, Published online 17 Jul 24. doi/10.1111/bjh.19648

Prabahran A.A, Koldej R, Chee L, Ritchie, D. Clinical features, pathophysiology and therapy of Poor Graft Function Post Allogeneic Stem Cell Transplantation. 2021, Blood Advances, doi:  10.1182/bloodadvances.2021004537

Prabahran A.A, Koldej R, Chee L, Wong E, Ritchie D.  Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation. 2021, Leukemia & Lymphoma, doi: 10.1080/10428194.2021.1872072